Acromegaly is a rare and chronic disorder characterized by excess growth hormone secretion and elevated insulin-like growth factor-1 levels, most often caused by a pituitary Adenoma.
- IONIS-GHR-LRx: Ionis Pharmaceuticals
- Mycapssa (Octreotide Capsules): Chiasma Pharma
- ATL1103: Antisense Therapeutics
- CAM2029: Camurus
- GT-02037 (G-SRIF): GlyTech
- Veldoreotide (COR-005, DG3173): Strongbridge Biopharma
- Paltusotine (CRN00808): Crinetics Pharmaceuticals
- MTD201: Midatech
- Lanreotide PRF: Ipsen
Scope of the Report
- The Acromegaly report provides an overview of therapeutic pipeline activity and therapeutic assessment of the products by development stage, product type, route of administration, molecule type, and MOA type for Acromegaly across the complete product development cycle, including all clinical and nonclinical stages.
- It comprises of detailed profiles of Acromegaly therapeutic products with key coverage of developmental activities, including technology, collaborations, licensing, mergers and acquisition, funding, designations and other product-related details
- Detailed Acromegaly research and development progress and trial details, results wherever available, are also included in the pipeline study.
- Coverage of dormant and discontinued pipeline projects along with the reasons if available across Acromegaly.
1. Report Introduction
2. Acromegaly
2.1. Overview
2.2. History
2.3. Acromegaly Symptoms
2.4. Causes
2.5.Pathophysiology
2.6. Acromegaly Diagnosis
2.6.1. Diagnostic Guidelines
3. Acromegaly Current Treatment Patterns
3.1. Acromegaly Treatment Guidelines
4. Acromegaly - DelveInsight's Analytical Perspective
4.1. In-depth Commercial Assessment
4.1.1. Acromegaly companies collaborations, Licensing, Acquisition -Deal Value Trends
4.1.1.1. Assessment Summary
4.1.2. Acromegaly Collaboration Deals
4.1.2.1. Company-Company Collaborations (Licensing / Partnering) Analysis
4.1.2.2. Company-University Collaborations (Licensing / Partnering) Analysis
4.1.2.3. Acromegaly Acquisition Analysis
5. Therapeutic Assessment
5.1. Clinical Assessment of Pipeline Drugs
5.1.1. Assessment by Phase of Development
5.1.2. Assessment by Product Type (Mono / Combination)
5.1.2.1. Assessment by Stage and Product Type
5.1.3. Assessment by Route of Administration
5.1.3.1. Assessment by Stage and Route of Administration
5.1.4. Assessment by Molecule Type
5.1.4.1. Assessment by Stage and Molecule Type
5.1.5. Assessment by MOA
5.1.5.1. Assessment by Stage and MOA
5.1.6. Assessment by Target
5.1.6.1. Assessment by Stage and Target
6. Acromegaly Late Stage Products (Phase-III)
7. Acromegaly Mid Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Acromegaly Discontinued Products
13. Acromegaly Product Profiles
13.1. Drug Name: Company
13.1.1. Product Description
13.1.1.1. Product Overview
13.1.1.2. Mechanism of action
13.1.2. Research and Development
13.1.2.1. Clinical Studies
13.1.3. Product Development Activities
13.1.3.1. Collaboration
13.1.3.2. Agreements
13.1.3.3. Acquisition
13.1.3.4. Patent Detail
13.1.4. Tabulated Product Summary
13.1.4.1. General Description Table
14. Acromegaly Key Companies
15. Acromegaly Key Products
16. Dormant and Discontinued Products
16.1. Dormant Products
16.1.1. Reasons for being dormant
16.2. Discontinued Products
16.2.1. Reasons for the discontinuation
17. Acromegaly Unmet Needs
18. Acromegaly Future Perspectives
19. Acromegaly Analyst Review
20. Appendix
21. Report Methodology
Media Contact
Company Name: DelveInsight
Contact Person: Priya Maurya
Email:Send Email
Phone: +919650213330
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/
